WebJan 10, 2014 · The FLINT trial, sponsored and conducted by the National Institute of Diabetes and Digestive and Kidney Diseases, studied the efficacy of a 25-mg. oral dose of obeticholic acid (OCA) in approximately half of 283 biopsy-confirmed NASH patients over a period of 72 weeks. Patients were randomized to receive either a 25-mg dose of OCA or … WebAug 11, 2024 · A high-profile Flint water crisis trial against two private engineering companies ended Thursday with a hung jury, a development that experts say makes a …
Farnesoid X nuclear receptor ligand obeticholic acid for non …
WebApr 23, 2015 · The Farnesoid X Receptor Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis Treatment (FLINT) trial was sponsored by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). FLINT enrolled 283 adult NASH patients at eight U.S. centers comprising the NIDDK's NASH clinical research network (CRN). WebMethods: In the Phase 2b FLINT trial, patients were randomised (1:1) to receive 25 mg OCA or placebo once daily for 72 weeks. Aspartate aminotransferase:platelet ratio index (APRI), fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease fibrosis score (NFS) were evaluated in serum at baseline and weeks 24, 48, 72 and 96. nash hill farm
REGENERATE: Design of a pivotal, randomised, phase 3 study ... - PubMed
WebNASH Treatment (FLINT) trial was a multicentre, randomised trial of 72 weeks of obeticholic acid versus placebo in patients with biopsy evidence of non-alcoholic … WebMar 3, 2015 · The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) trial was a multicentre, randomised trial of 72 weeks of obeticholic acid versus … WebAug 29, 2024 · The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial (FLINT). FLINT found that obeticholic acid (OCA) treatment was associated with … members 1st hummelstown pa